Effectiveness of enalapril in combination with low-dose Hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients

Middlemost, Shirley; Tager, Robin; Davis, Jean; Sareli, Pinhas

doi:10.1016/0002-9149(94)90289-5

Cited by 32 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,21 The ability of lisinopril to produce a transient effect on 24-h ambulatory blood pressures (day 28) and the apparent sustained antihypertensive actions (albeit modest) of lisinopril, as determined from office pressure measurements over the 56-day treatment period in our study, is in contrast to the lack of effect of ACE inhibitor monotherapy on blood pressure previously shown to occur in black hypertensives recruited from the same geographic region. 16 Not all studies have failed to show an antihypertensive action of ACE inhibitor monotherapy in black subjects. Notably, Cummings et al 22 showed a significant antihypertensive response, as determined using office blood pressure measurements, to lisinopril in a group of 20 black and four white hypertensives.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects

Norton

1999

American Journal of Hypertension

View full text Add to dashboard Cite

Our objective was to evaluate the safety and antihypertensive efficacy of sampatrilat, a novel dual inhibitor of both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP), in subjects poorly responsive to ACE inhibitor monotherapy. The ability of sampatrilat (50 to 100 mg daily) (n ‫؍‬ ‫؍‬ 28) to lower blood pressure was compared with that of the ACE inhibitor lisinopril (10 to 20 mg daily) (n ‫؍‬ ‫؍‬ 30) using a double-blind, randomized, parallel group study design over a 56-day treatment period in black hypertensives. Changes in systolic (SBP) and diastolic (DBP) blood pressure were determined using repeated ambulatory blood pressure (ABP) monitoring. Both sampatrilat and lisinopril decreased plasma ACE concentrations after 28 and 56 days. The decrease in plasma ACE concentrations (U/L) was greater after lisinopril (؊ ؊9.33 ؎ ؎ 0.52) as compared with sampatrilat (؊ ؊6.31 ؎ ؎ 0.70) (P ‫؍‬ ‫؍‬ .0001) therapy. Lisinopril, but not sampatrilat, increased plasma renin activity. Lisinopril produced a transient decrease in mean 24-h ABP (mm Hg) at 28 days (SBP ‫؍‬ ‫؍‬ ؊ ؊9.0 ؎ ؎ 2.3, DBP ‫؍‬ ‫؍‬ ؊ ؊5.7 ؎ ؎ 1.3; P < < .01), which returned to pretreatment values by 56 days of therapy. Alternatively, sampatrilat produced a sustained decrease in mean ABP over the 56-day treatment period (day 28: SBP ‫؍‬ ‫؍‬ ؊ ؊7.3 ؎ ؎ 1.8, DBP ‫؍‬ ‫؍‬ ؊ ؊5.2 ؎ ؎ 1.2; P < < .01: day 56: SBP ‫؍‬ ‫؍‬ ؊ ؊7.8 ؎ ؎ 1.5; DBP ‫؍‬ ‫؍‬ ؊ ؊5.2 ؎ ؎ 0.95; P < < 0.01) with a greater treatment effect on DBP than that of lisinopril at day 56 (P ‫؍‬ ‫؍‬ .05). Treatment-emergent adverse events were noted to be similar between both treatment groups. We conclude that the antihypertensive actions of ACE/NEP inhibitor monotherapy in black subjects offers a novel therapeutic approach to patients otherwise resistant to the sustained antihypertensive actions of ACE inhibitor monotherapy. Am J Hypertens 1999; 12:563-571

show abstract

Section: Discussionmentioning

confidence: 99%

“…Black hypertensives were chosen as the study population, as these subjects have previously been shown to be either unresponsive or only partially responsive to ACE inhibitor monotherapy. 16,17…”

mentioning

confidence: 99%

Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects

Norton

1999

American Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…4 (3) Patients of African ancestry have poor BP responses to RAS blockers and yet these agents still regress LVH. 6 Whether this masks the impact of BP changes on LVH regression in this group is not known.…”

mentioning

confidence: 95%

“…Indeed, previous data from our group suggest that the use of angiotensin-converting enzyme inhibitors (ACEI) result in reductions in LV mass (LVM) in hypertensives of African ancestry in association with little change in BP. 6 We were therefore concerned that the effects of reductions in BP on regression of LVM index (LVMI) may be eradicated by the reduction in LVMI, which is associated with minimal change in BP in response to ACEI. The question of whether decreases in BP predict regression of LVH is of particular importance in hypertensive groups of African ancestry who have higher LVH 7 and in whom electrocardiograph criteria are poor indicators of LVH, 8 thus necessitating the use of other clinical indicators of regression of LVH.…”

mentioning

confidence: 99%

Change in blood pressure predicts regression of cardiac hypertrophy in patients of African ancestry receiving agents influencing the renin–angiotensin system

et al. 2005

View full text Add to dashboard Cite

“…1), is a diuretic agent used for hypertension treatment that reduces plasma volume by increasing the excretion of sodium, chloride, water and to a lesser extent of potassium ion [1][2][3]. It is often used in mixture with other antihypertensive drugs such as beta blockers, angiotensin-converting enzyme inhibitors, or more recently, as angiotensin receptor blockers [4][5][6][7][8][9][10]. A range of analytical techniques, such as high performance liquid chromatography (HPLC) [11][12][13][14][15][16], capillary electrophoresis [17,18], spectrophotometry [19,20] and chemometric techniques [21][22][23] are used for its determination in pharmaceutical samples.…”

Section: Introductionmentioning

confidence: 99%

Application of molecularly imprinted polymer for solid phase extraction and preconcentration of Hydrochlorothiazide in pharmaceutical and serum sample analysis

Rezaei

Mallakpour

Rahmanian

2010

JICS

View full text Add to dashboard Cite

A new polymeric sorbent prepared by utilizing molecular imprinting technology was used for the selective extraction of hydrochlorothiazide (HCT) from pharmaceutical and human serum sample. The molecularly imprinted polymer (MIP) was prepared using HCT as the template, methacrylic acid (MAA) as the functional monomer, ethylene glycol dimethacrylate (EDMA) as the cross-linker monomer, and dimethylformamide (DMF) as a solvent. The optimized conditions of MIPs as a selective sorbent for the preconcentration of the HCT were studied. The results showed that the drug could be quantitatively and selectively maintained in the column to be then eluted from the sorbent by using methanol-acetic acid mixture (9:1). HCT could be determined spectrophotometrically at λ max = 270 nm. This method made it possible to quantitize HCT in the range of 0.1-21.0 µg ml -1 , by less than 0.55% of RSD%, with a detection limit (S/N = 3) of 0.073 ng ml -1 . The preconcentration factor of 1000, recoveries of up to 96% and retention capacity of 75.0 mg g -1 were achieved using this technique.

show abstract

Effectiveness of enalapril in combination with low-dose Hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients

Cited by 32 publications

References 17 publications

Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects

Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects

Change in blood pressure predicts regression of cardiac hypertrophy in patients of African ancestry receiving agents influencing the renin–angiotensin system

Application of molecularly imprinted polymer for solid phase extraction and preconcentration of Hydrochlorothiazide in pharmaceutical and serum sample analysis

Contact Info

Product

Resources

About